Soluble herpesvirus glycoprotein complex vaccine
AssigneeThe Trustees of the University of Pennsylvania
InventorsGary H. Cohen, Roselyn J. Eisenberg, Tao Peng, Gary Dubin
Life of this patent
Estimating the term…
Abstract
The invention is directed to a herpes simplex virus vaccine comprising a herpes simplex virus glycoprotein H-glycoprotein L complex. The invention is also directed to a vaccine comprising a DNA encoding a herpes simplex virus glycoprotein H-glycoprotein L complex. Also included is an antibody which specifically binds to a herpes simplex virus glycoprotein H-glycoprotein L complex and DNA encoding the same.
Claims36
A vaccine comprising a soluble herpes simplex virus gHt-gL complex suspended in a pharmaceutically acceptable carrier.
A vaccine comprising an isolated DNA encoding a soluble herpes simplex virus gHt-gL complex suspended in a pharmaceutically acceptable carrier.
A herpes simplex virus neutralizing antibody which specifically binds to a soluble herpes simplex virus gHt-gL complex.
An isolated DNA encoding a herpes simplex virus neutralizing antibody which specifically binds to a soluble herpes simplex virus gHt-gL complex.
A preparation of a soluble herpes simplex virus gHt-gL complex.
A substantially pure preparation of a soluble herpes simplex virus gHt-gL complex.
A cell, the DNA of said cell encoding a soluble herpes simplex virus gHt-gL complex.
A method of modifying a cell to render it capable of secreting a soluble herpes simplex virus gHt-gL complex comprising introducing into said cell DNA encoding a truncated form of herpes simplex virus gH being gHt and full length herpes simplex virus gL, wherein said gHt and said gL are expressed in and secreted from said cell.
An isolated DNA comprising DNA encoding a herpes simplex virus gHt and a substantially full length herpes simplex virus gL.
Dependencies are inferred from the claim text.